Leo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline"

Leo Pharma must create growth and secure a proper pipeline. ”The rest can be figured out if those two things are sorted,” says Peter Haahr, CEO of Leo Pharma’s majority shareholder, the Leo Foundation.

Photo: Leo Pharma/PR

Several top managers have been replaced and the organization’s management looks markedly different from just a few years ago. The company is leaking money, and has announced that 1,000 positions are to be terminated.

The main owner of pharmaceutical company Leo Pharma is now saying that it is not possible to save up for success alongside capital fund Nordic Capital ahead of the expected IPO within four or five years.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs